Mingorance Ana
Dracaena Consulting SL, Madrid 28036, Spain.
ACS Med Chem Lett. 2018 Oct 1;9(10):962-964. doi: 10.1021/acsmedchemlett.8b00438. eCollection 2018 Oct 11.
Previously neglected by the pharmaceutical industry, rare diseases and orphan drugs are rapidly becoming mainstream. Both market forces and technology enablers are responsible for this migration and combine to create multiple business approaches. This viewpoint discusses the drivers that attract different companies into this booming orphan drug space.
罕见病和孤儿药此前被制药行业忽视，如今正迅速成为主流。市场力量和技术推动因素共同促成了这一转变，并催生了多种商业模式。本文观点探讨了吸引不同公司进入这一蓬勃发展的孤儿药领域的驱动因素。
